Ming-Lung Ho1, Wei-Ke Kuo2, Lichieh J Chu1,3,4, I-Hsin Yeh1, Chung-Wei Fan5, Hsin-I Chang1, Cho-Li Yuan6, Ting-Yu Chou1, Hoang-Yang Chen7, Shih-Wei Yang8, Liang-Che Chang9, Minzhen Luo1, Timothy H Wu1, Yi-Feng I Chang3, Chia-Jung Yu3,10,11, Chung-Ching Hua12, Wailap V Ng13,14,15. 1. Department of Biotechnology and Laboratory Science in Medicine, National Yang Ming University, Taipei, Taiwan, R.O.C. 2. Division of Pulmonary, Critical Care and Sleep Medicine, Chang Gung Memorial Hospital, Keelung and Chang Gung University, Taoyuan, Taiwan, R.O.C. 3. Molecular Medicine Research Center, Chang Gung University, Taoyuan, Taiwan, R.O.C. 4. Liver Research Center, Chang Gung Memorial Hospital, Linkou, Taiwan, R.O.C. 5. Division of Colon and Rectal Surgery, Chang Gung Memorial Hospital, Keelung and Chang Gung University, Taoyuan, Taiwan, R.O.C. 6. Liver Research Unit, Chang Gung Memorial Hospital, Keelung and Chang Gung University, Taoyuan, Taiwan, R.O.C. 7. Division of General Surgery, Department of Surgery, Chang Gung Memorial Hospital, Keelung and Chang Gung University, Taoyuan, Taiwan, R.O.C. 8. Department of Otolaryngology, Head and Neck Surgery, Chang Gung Memorial Hospital, Keelung and Chang Gung University, Taoyuan, Taiwan, R.O.C. 9. Department of Pathology, Chang Gung Memorial Hospital, Keelung and Chang Gung University, Taoyuan, Taiwan, R.O.C. 10. Department of Cell and Molecular Biology, College of Medicine, Chang Gung University, Taoyuan, Taiwan, R.O.C. 11. Department of Thoracic Medicine, Chang Gung Memorial Hospital, Linkou, Taiwan, R.O.C. 12. Division of Pulmonary, Critical Care and Sleep Medicine, Chang Gung Memorial Hospital, Keelung and Chang Gung University, Taoyuan, Taiwan, R.O.C. wvng@ym.edu.tw hc2008@cgmh.org.tw. 13. Department of Biotechnology and Laboratory Science in Medicine, National Yang Ming University, Taipei, Taiwan, R.O.C. wvng@ym.edu.tw hc2008@cgmh.org.tw. 14. Institute of Biomedical Informatics, National Yang Ming University, Taipei, Taiwan, R.O.C. 15. Department of Biochemistry, Kaohsiung Medical University, Kaohsiung, Taiwan, R.O.C.
Abstract
BACKGROUND/AIM: The aim of this study was to evaluate N-acetylgalactosamine-6-sulfatase (GALNS) as a new biomarker candidate for detecting lung cancer. Glycodelin or PAEP, the serum levels of which are known to be elevated in lung and other cancers, served as a benchmark for comparison. PATIENTS AND METHODS: A total of 170 serum samples from healthy controls and patients with pneumonia, lung cancer, breast cancer, colon cancer, liver cancer, and head and neck cancer were analyzed for the levels of GALNS and PAEP by ELISA. RESULTS: The median serum levels of GALNS and PAEP in all cancer types as well as pneumonia patients were significantly higher than those of the healthy controls. CONCLUSION: In addition to previously known cancers, the median serum levels of PAEP were also found to be higher in liver and head and neck cancer patients. GALNS and PAEP are promising general biomarkers for multiple cancers and deserve further evaluation. Copyright
BACKGROUND/AIM: The aim of this study was to evaluate N-acetylgalactosamine-6-sulfatase (GALNS) as a new biomarker candidate for detecting lung cancer. Glycodelin or PAEP, the serum levels of which are known to be elevated in lung and other cancers, served as a benchmark for comparison. PATIENTS AND METHODS: A total of 170 serum samples from healthy controls and patients with pneumonia, lung cancer, breast cancer, colon cancer, liver cancer, and head and neck cancer were analyzed for the levels of GALNS and PAEP by ELISA. RESULTS: The median serum levels of GALNS and PAEP in all cancer types as well as pneumoniapatients were significantly higher than those of the healthy controls. CONCLUSION: In addition to previously known cancers, the median serum levels of PAEP were also found to be higher in liver and head and neck cancerpatients. GALNS and PAEP are promising general biomarkers for multiple cancers and deserve further evaluation. Copyright